Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Company
ABVC BIOPHARMA, INC. (ABVC)
Standardized SEC financial data for ABVC BIOPHARMA, INC. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001173313 · NASDAQ · Pharmaceutical Preparations.
Return on equity
-59.5%
Free cash flow
-$3.0M
Current ratio
0.41×
EPS (diluted)
$-0.39
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
USD
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
$483K
$356K
$970K
$152K
$510K
$296K
Cost of revenue
$19K
$5K
$286K
$302K
$763
—
Gross profit
$464K
$351K
$683K
-$150K
$509K
—
R&D expense
$550K
$1.0M
Standardized from ABVC BIOPHARMA, INC.'s SEC filings — per-share figures split-adjusted. Full history via the API.